Market Data 
Markets
Replies to post #14127 on United Health Products Inc (UEEC)
SEC Transactions Last 2 Years
Trans Date Filer Ownership Type Price Shares
05/12/2023 THOM BRIAN DAVID
Officer Direct Sell 0.19 300,000
04/17/2023 THOM BRIAN DAVID
Officer Direct Acquisition (Non Open Market) 0.22 309,375
01/13/2023 THOM BRIAN DAVID
Officer Direct Acquisition (Non Open Market) 0.27 225,000
"We have has seen a .05 increase from 10/14 of .09 to the current .145. Do your due diligence but clearly the market is optimistic that the pps is the result of oversold and nefarious manipulation by hedge fund traders and their brokers selling to each other driving the pps down.The PMA submission and FDA news coming within 30 days."
"FDA Selects HemoStyp ® for CtQ Pilot ProgramHenderson, Nevada – December 4, 2017 –United Health Products, Inc. (UHP) (OTC: UEEC), manufacturer and marketer of HemoStyp®, a patented hemostaticgauze for the healthcare and wound care sectors, today announced that it is proceeding with its application for HemoStyp under the FDA’s new and innovative CtQPilot Program. The FDA selected UHP’s HemoStyp as only one of nine participants for the program. UHP management has scheduled its first face-to-face meetingwith FDA experts for January 17, 2018 to provide the agency with whatever information it needs to advance the application for premarket approval (PMA).The FDA has stated that it intends to work collaboratively with pilot program participants during the review of their PMA submission to define characteristics ofthe device that are critical to product quality, and how these characteristics are controlled in design and manufacturing prior to the postmarket inspection. For pilotprogram participants, the FDA would forego conducting the standard PMA preapproval inspection, and a postmarket inspection focusing on the PMA applicant’simplementation of the critical to quality characteristics would be conducted instead.
The CtQ Pilot Program was created to identify products that have a chemical makeup of demonstrated safe interaction with the body –as evidenced by years ofprior product usage and studies-- to be approved for Class III internal surgical use. The program’s intent is to allow products that have demonstrated repeated safeinteraction to enter the market in a more efficient manner. This application will run simultaneously with the company’s prior Class II application for expandedindication. The market for 2017 internal surgical market for hemostatic products is estimated at in excess of seven billion dollars, and is expected to grow at 7.1%over the next few years, to reach more than $8.3 billion by 2022. (http://industryarc.com/Report/15189/hemostats-market.html)
Concurrent with its CtQ Pilot Program participation, UHP reaffirms that its current Class II application – Expanded Indication submission with the US FDA--continues to progress, and is in an advanced stage of review"
10/25/24 1:56 PM
10/25/24 1:56 PM
AI
